The prevalence rate of cardiovascular system and cerebrovascular diseases is drastically increasing in China with age decrease of affected population. The mortality rate of cardiovascular and cerebrovascular events remains the first one among of all causes of death. At present, there are still many unmet clinical needs in the cardiovascular and cerebrovascular field, especially, the high rate of disability after strokes, the risk of heart failure after myocardial infarction thrombolysis and interventional therapy. This situation around unmet needs make the research and development of related chemicals and natural compounds very attractive for cardiovascular scientific community with further transfer into clinical stage, that in turn gives rise to a need in qualified clinical trial service providers. At the same time, the single cell sequencing technology application in the studies of cardiovascular diseases pathogenesis and progression and the development of cardiomyocytes regenerative therapies emphasizes the pivotal role of cardiac inflammation in disease pathogenesis and progression. Gene therapy became research hot spot. PAGln represents a new intestinal microbiota dependent metabolite that promotes CVD, making it to be a potential target for personalized therapy in the future. Pluripotent stem cell technology also entered clinical trial stage as potential treatment after cardiac damage. The innovation of drug development makes cardiac xenotransplantation possible.

Proswell Medical Development Center Cardiovascular and Cerebrovascular team keeps up with the times and is aware of research hot spots and trends in clinical trials both at home and abroad. The team is led by senior first line clinical experts who have been engaged in clinical work and research for more than 20 years. They have rich professional experience in the diagnostic and treatment of cardiovascular and cerebrovascular diseases such as coronary heart disease, hypertension, heart failure, arrhythmia, stroke, and other diseases. The diverse and excellent cooperation relationship with industry experts and hospitals gives an opportunity to our sponsor to solve serious problems faced during the study and facilitates the conducting of clinical trials of all phases.

Our cardiovascular and cerebrovascular dedicated medical team provides one stop medical service for all indications and all trial phases for the new investigational drug, including but not limited to: CDP development, medical writing, Health Authority communication, protocol development, medical monitoring, and CSR development.